Company intelligence / Profile preview

Viosera Therapeutics

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Viosera Therapeutics is a biotechnology company dedicated to overcoming the global crisis of antibiotic resistance. The company utilizes a proprietary high-throughput discovery platform that combines machine learning with experimental biology to identify novel drug combinations and new chemical entities. By mapping the resistance landscape of pathogens, Viosera aims to develop therapies that are evolution-resistant and effective against multi-drug resistant (MDR) bacteria. Their current focus includes addressing high-priority threats such as methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative infections.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

cephradine

Unknown

Beyond the preview

Go deeper on Viosera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viosera Therapeutics.

Explore the full profile